STAT+: Pharmalittle: We’re reading about China’s homegrown GLP-1 drugs, a puzzling FDA rejection, and more — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly is investing heavily in India to manufacture and export drugs globally, driven by the success of its weight-loss medication and the growing obesity epidemic.
- The FDA rejected Disc Medicine's bitopertin, a porphyria treatment, despite it being part of a new fast-track review program, underscoring the program's limitations.
- China's drug industry is rapidly advancing, particularly in the GLP-1 space, signaling increasing competition and innovation in the global pharmaceutical market (per STAT News).
Why it matters: These developments signal shifts in global pharmaceutical manufacturing, regulatory processes, and the race to address major health challenges like obesity and rare diseases, impacting both patients and the industry.
Ask SkimNews
